Full Text View
Tabular View
Study Results
Related Studies
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
This study has been completed.
Study NCT01185028   Information provided by National Institutes of Health Clinical Center (CC)

First Received on August 18, 2010.   Last Updated on March 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C Infection
HIV Infection
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hepatitis
Hepatitis A
Hepatitis C
HIV Infections
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Liver Diseases
Picornaviridae Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Additional drug interventions recognized in this trial
Interferons
Nitazoxanide
Peginterferon alfa-2a
Ribavirin
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiparasitic Agents
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institutes of Health Clinical Center (CC)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services